Zithromax azithromycin 200mg

One can also take Zithromax in liquid form, or even in extended release liquid form. How to Use Zithromax When FDA first approved Zithromax as an effective antibiotic, it was used in the treatment of uncomplicated skin infections, sore throats , and such illnesses as adult sinusitis and acute bronchitis.

Later, a number of other illnesses were included in this list, such as the genital ulcer disease chlamydia , as well as urethritis, pneumonia, and pharyngitis, among others. However, even though Zithromax is appropriate for treating pneumonia, it is categorically forbidden for those patients suffering from pneumonia who have a risk factor with regard to taking oral medication.

Another crucial aspect to consider when taking Zithromax is the effectiveness of the medication in combating only certain types of bacteria. If the patient takes an excessive dosage of the drug to treat unsusceptible bacteria, his or her condition will deteriorate, and bacteria that are entirely resistant to Zithromax treatment will develop. However, there are numerous of cases in which doctors have prescribed Azithromycin mg dosage for illnesses other than those mentioned above.

For example, sexually transmitted diseases such as chlamydia and gonorrhea, as well as diarrhea, babesiosis, whooping cough, and many other infections can be treated successfully with this medication. In addition, patients who have experienced sexual assaults or medical procedures are often prescribed mg dosage. Alcohol does not reduce the effectiveness of Azithromycin, but it is best to avoid alcohol when taking Zithromax.

How Azithromycin Works In principle, how Azithromycin works is quite simple. This macrolide antibiotic prevents the growth of infected bacteria by impeding the synthesis of the cell proteins. Possible Side Effects As with any medication, Azithromycin has side effects. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin.

Providers should consider the risk of QT prolongation which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including: Elderly patients may be more susceptible to drug-associated effects on the QT interval. Treatment with antibacterial agents alters the normal flora of the colon , leading to overgrowth of C.

Hypertoxin-producing strains of C. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. Exacerbation Of Myasthenia Gravis Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azitrhromycin therapy. Antibacterial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating gonorrhea or syphilis.

All patients with sexually transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antibacterial therapy and follow-up tests for these diseases should be initiated if infection is confirmed.

Development Of Drug-Resistant Bacteria Prescribing ZITHROMAX in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of Fertility Long-term studies in animals have not been performed to evaluate carcinogenic potential. If your infection gets worse or you do not start to feel better within a few days or a new infection develops, go back and see your doctor.

How to give Zithromax Suspension in children less than 3 years of age If your child is under three years of age or weighs up to 15kg in bodyweight, you should measure the dose as clearly as possible using the 10ml oral dosing syringe provided. The syringe is graduated in 0. Instructions for the syringe Filling the syringe with medicine 1. Shake the bottle before use and remove the child-proof cap. An adaptor for the syringe should have been fitted into the neck of the bottle of medicine by the pharmacist.

If this has not been done, take off the adaptor from the syringe and fit to the neck of the bottle as shown. The adaptor is so that you can fill the syringe with medicine from the bottle. Check the dispensing label attached by your pharmacist to see how much medicine needs to be taken. While the bottle is sitting on a firm, flat surface, hold it steady with one hand. With the other hand insert the tip of the syringe into the adaptor.

Turn the bottle upside down while holding the syringe in place. Theoretically, perphenazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation.

Major Chloramphenicol and macrolides are bactericidal or bacteriostatic via the same or similar mechanisms of action. Antagonism in vitro has been demonstrated. Minor Until more data are available, the manufacturer of azithromycin recommends caution and careful monitoring of patients who receive azithromycin with phenytoin. Azithromycin was not implicated in clinical trials with drug interactions with phenytoin. However, specific drug interaction studies have not been performed with the combination of azithromycin and phenytoin.

Major Pimavanserin may cause QT prolongation and should generally be avoided in patients receiving other medications known to prolong the QT interval, such as azithromycin. Coadministration may increase the risk for QT prolongation. Severe Concurrent use of pimozide and macrolides e. Elevated pimozide concentrations occurring through inhibition of CYP3A4 can lead to QT prolongation, ventricular arrhythmias, and sudden death. Two sudden deaths have been reported when clarithromycin was added to pimozide therapy.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering posaconazole with azithromycin. Posaconazole has been associated with prolongation of the QT interval as well as rare cases of torsade de pointes Pravastatin: Major Due to the potential for QT interval prolongation with primaquine, caution is advised with other drugs that prolong the QT interval.

Drugs with a possible risk for QT prolongation and TdP that should be used cautiously and with close monitoring with primaquine include azithromycin.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering procainamide with azithromycin. Procainamide is associated with a well-established risk of QT prolongation and TdP, and cases of QT prolongation and TdP have been reported with the post-marketing use of azithromycin. Minor Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and prochlorperazine should be used together cautiously.

Prochlorperazine is associated with a possible risk for QT prolongation. Theoretically, prochlorperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering propafenone with azithromycin. Azithromycin has been associated with cases of QT prolongation and TdP, reported during the postmarketing period. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering quetiapine with azithromycin.

Limited data, including some case reports, suggest that quetiapine may be associated with a significant prolongation of the QTc interval in rare instances. Additionally, azithromycin has been associated with cases of QT prolongation and TdP, reported during the post-marketing period.

Major Concurrent use of quinine and azithromycin should be avoided due to an increased risk for QT prolongation and torsade de pointes TdP. Quinine has been associated with prolongation of the QT interval and rare cases of TdP. Ranolazine is also associated with a possible risk for QT prolongation and torsade de pointes TdP ; therefore, concomitant use may have additive risk. Azithromycin is also a substrate for and an inhibitor of P-glycoprotein transport, an energy-dependent drug efflux pump.

The inhibition of P-glycoprotein, by drugs such as ranolazine may result in an increase in the concentration of azithromycin. Similarly, ranolazine also is a substrate for and an inhibitor of P-glycoprotein transport. Coadministration with azithromycin may result in an increase in the plasma concentration of ranolazine. If ranolazine and azithromycin are coadministered, patients should be monitored closely for adverse effects of each agent. Major Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and regadenoson should be used together cautiously.

Regadenoson has been associated with QT prolongation. Major Avoid coadministration of ribociclib with azithromycin due to an increased risk for QT prolongation and torsade de pointes TdP. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. There have been case reports of QT prolongation and Td with the use of azithromycin in postmarketing reports. Concomitant use may increase the risk for QT prolongation.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , cautious use of risperidone with azithromycin is advised. If coadministration is chosen, and the patient has known risk factors for cardiac disease or arrhythmia, then the patient should be closely monitored clinically. Reports of QT prolongation and TdP during risperidone therapy are noted by the manufacturer, primarily in the overdosage setting.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering romidepsin with azithromycin. If these drugs must be coadministered, periodic ECG and electrolyte monitoring is recommended.

Romidepsin has been reported to prolong the QT interval, and cases of QT prolongation and TdP have been reported with the postmarketing use of azithromycin.

Major Avoid administering saquinavir boosted with ritonavir with other drugs that may prolong the QT interval, such as azithromycin. Saquinavir boosted with ritonavir increases the QT interval in a dose-dependent fashion, which may increase the risk for serious arrhythmias such as torsade de pointes TdP.

If no acceptable alternative therapy is available, perform a baseline ECG prior to initiation of concomitant therapy and carefully follow monitoring recommendations. Major There have been postmarketing reports of QT prolongation and torsade de pointes TdP during treatment with sertraline and the manufacturer of sertraline recommends avoiding concurrent use with drugs known to prolong the QTc interval.

Sodium picosulfate; Magnesium oxide; Anhydrous citric acid: Major Prior or concomitant use of antibiotics with sodium picosulfate; magnesium oxide; anhydrous citric acid may reduce efficacy of the bowel preparation as conversion of sodium picosulfate to its active metabolite bis- p-hydroxy-phenyl -pyridylmethane BHPM is mediated by colonic bacteria.

If possible, avoid coadministration. Therefore, these antibiotics should be taken at least 2 hours before and not less than 6 hours after the administration of sodium picosulfate; magnesium oxide; anhydrous citric acid solution. Major Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and solifenacin should be used together cautiously.

Solifenacin has been associated with dose-dependent prolongation of the QT interval. TdP has been reported with postmarketing use, although causality was not determined. This should be taken into consideration when prescribing solifenacin to patients taking other drugs that are associated with QT prolongation.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering sorafenib with azithromycin. Sorafenib has been associated with QT prolongation, and cases of QT prolongation and TdP have been reported with the use of azithromycin during the post-marketing period. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , cautious use of sotalol with azithromycin is advised.

Sotalol administration is also associated with QT prolongation and TdP. Proarrhythmic events should be anticipated after initiation of sotalol therapy and after each upward dosage adjustment. Other drugs, such as sparfloxacin, have been specifically established to have a causal association with QT prolongation and torsade de pointes and are contraindicated for use with drugs that potentially cause QT prolongation, such as azithromycin.

Major Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and sulfamethoxazole; trimethoprim should be used together cautiously.

QT prolongation resulting in ventricular tachycardia and TdP has been reported during postmarketing use of sulfamethoxazole; trimethoprim. In addition, there have been case reports of QT prolongation and TdP with the use of azithromycin in postmarketing reports. Major Monitor patients for QT prolongation if coadministration of azithromycin with sunitinib is necessary.

Sunitinib can cause dose-dependent QT prolongation, which may increase the risk for ventricular arrhythmias, including torsades de points TdP. Prolongation of the QT interval and TdP have been spontaneously reported during azithromycin postmarketing surveillance. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering tacrolimus with azithromycin. Tacrolimus causes QT prolongation, and cases of QT prolongation and TdP have been reported with the post-marketing use of azithromycin.

Major Caution is advised with the concomitant use of tamoxifen with azithromycin due to an increased risk of QT prolongation and torsade de pointes TdP. Tamoxifen has been reported to prolong the QT interval, usually in overdose or when used in high doses.

Rare case reports of QT prolongation have also been described when tamoxifen is used at lower doses. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering telavancin with azithromycin. Telavancin has been associated with QT prolongation, and cases of QT prolongation and TdP have been reported with the post-marketing use of azithromycin.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering telithromycin with azithromycin.

Telithromycin is associated with QT prolongation and TdP, and cases of QT prolongation and TdP have been reported with the post-marketing use of azithromycin. Severe Coadministration is contraindicated due to the risk for QT prolongation and torsade de pointes TdP.

Consider alternative antihistamine therapy. Terfenadine has been specifically established to have a causal association with QT prolongation and TdP and is contraindicated for use with drugs that potentially cause QT prolongation, such as azithromycin.

There have been case reports of QT prolongation and torsade de pointes TdP with the use of azithromycin in postmarketing reports. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering tetrabenazine with azithromycin.

Tetrabenazine causes a small increase in the corrected QT interval QTc , and cases of QT prolongation and TdP have been reported with the post-marketing use of azithromycin. Severe Because of the potential for torsade de pointes TdP , use of azithromycin with thioridazine is contraindicated. Thioridazine is associated with a well-established risk of QT prolongation and TdP. Thioridazine is considered contraindicated for use along with agents that, when combined with a phenothiazine, may prolong the QT interval and increase the risk of TdP.

Major Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and tizanidine should be used together cautiously. Tizanidine administration may result in QT prolongation. Major Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and tolterodine should be used together cautiously. Tolterodine has been associated with dose-dependent prolongation of the QT interval, especially in poor CYP2D6 metabolizers.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering toremifene with azithromycin. Toremifene has been shown to prolong the QTc interval in a dose- and concentration-related manner, and cases of QT prolongation and TdP have been reported with the post-marketing use of azithromycin.

In addition, there are post-marketing reports of torsade de pointes TdP. Therefore, the manufacturer recommends avoiding trazodone in patients receiving other drugs that increase the QT interval, such as azithromycin. Minor Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering trifluoperazine with azithromycin. Trifluoperazine is associated with a possible risk for QT prolongation.

Theoretically, trifluoperazine may increase the risk of QT prolongation if coadministered with other drugs that have a risk of QT prolongation. Major Due to a possible risk for QT prolongation and torsade de pointes TdP , azithromycin and triptorelin should be used together cautiously. Major Avoid coadministration of vandetanib with azithromycin due to an increased risk of QT prolongation and torsade de pointes TdP.

An interruption of vandetanib therapy or dose reduction may be necessary for QT prolongation. Vandetanib can prolong the QT interval in a concentration-dependent manner; TdP and sudden death have been reported in patients receiving vandetanib.

Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering vardenafil with azithromycin.

Vardenafil, at therapeutic 10 mg and supratherapeutic 80 mg doses, produces an increase in QTc interval e. Major Vemurafenib has been associated with QT prolongation. If vemurafenib and another drug, such as azithromycin, that is associated with a possible risk for QT prolongation and torsade de pointes TdP must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering venlafaxine with azithromycin.

Venlafaxine is associated with a possible risk of QT prolongation; TdP has been reported with postmarketing use. Azithromycin has also been associated with postmarketing reports of QT prolongation and TdP. Major Due to the potential for QT prolongation and torsade de pointes TdP , caution is advised when administering voriconazole with azithromycin.

Voriconazole has been associated with prolongation of the QT interval and rare cases of arrhythmias, including TdP. There have also been case reports of QT prolongation and TdP with azithromycin. Major Due to an increased risk for QT prolongation and torsade de pointes TdP , caution is advised when administering vorinostat with azithromycin. Vorinostat is associated with a risk of QT prolongation, and cases of QT prolongation and TdP have been reported with the postmarketing use of azithromycin.

Moderate Azithromycin did not affect the prothrombin time response to a single dose of warfarin. Compared to other macrolides, azithromycin has less of an effect on cytochrome P isoenzymes. Reports of an interaction between azithromycin and warfarin have been made to the manufacturers suggesting that concomitant administration may potentiate the effects of warfarin. Monitor the INR in patients who receive warfarin and azithromycin concurrently as a potential interaction may occur.

The concurrent use of other macrolides and warfarin in medical practice has been associated with increased anticoagulant effects. Severe According to the manufacturer, ziprasidone is contraindicated with any drugs that list QT prolongation as a pharmacodynamic effect when this effect has been described within the contraindications or bolded or boxed warnings of the official labeling for such drugs.

Clinical trial data indicate that ziprasidone causes QT prolongation. In one study, ziprasidone increased the QT interval 10 msec more than placebo at the maximum recommended dosage. Comparative data with other antipsychotics have shown that the mean QTc interval prolongation occurring with ziprasidone exceeds that of haloperidol, quetiapine, olanzapine, and risperidone, but is less than that which occurs with thioridazine.

Given the potential for QT prolongation, ziprasidone is contraindicated for use with drugs that are known to cause QT prolongation with potential for torsades de pointes including azithromycin. Adequate and well-controlled studies of azithromycin use in pregnant women are lacking.

Tags: alcohol and motrin 600mg keppra 25mg buy transdermal verapamil